The company was set-up to develop and commercialise the research outputs of a long-running programme originating from the University of Melbourne working in collaboration with CSL.
The Nanopatch, a revolutionary new needle-free device for delivering vaccines, has won a $15 million capital injection (pun intended), but also was an award winner at World Vaccine Congress. After eight years of research, the Nanopatch looks set to revolutionise vaccination delivery forever.
Vaxxas Pty. Ltd. has won a $15 million investment from venture groups led by OneVentures. Other investors include Brandon Capital Partners, the Medical Research Commercialisation Fund and U.S.-based HealthCare Ventures. Vaxxas is the first Queensland company to be funded under the Bio Capital Fund, which has swelled to nearly $250 million, established last year with the help of Health Care Ventures and Eli Lilly, among others. The investment was negotiated in the main by UniQuest Pty Limited, the University of Queensland’s main commercialisation company.
End of content
End of content
GET THIS AMAZEBALLS THING!
Click the button to get it now
